Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-identical stem cell and cord blood co-infusion in very high-risk hematologic malignancies
NL-OMON35879Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2011
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hematopoietic malignancies, leukemia, lymphoma and 2 more, sponsored by University Medical Center Utrecht. Primary endpoints: Transplantation-related mortality and Anti-tumor response mechanism from both grafts. Started Oct 2011; status: active, not recruiting.
02
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)aplastic anemia
Beyond the preview
Go deeper on NL-OMON35879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35879.